Ignite Creation Date:
2024-05-06 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05348161
Status:
RECRUITING
Last Update Posted:
2022-04-27
First Post:
2022-01-29
Brief Title:
Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer
Status:
RECRUITING
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dynamic multiomics explore the efficacy and mechanism of anti-HER2 immunotherapy of HER2 Positive GC
Detailed Description:
The investigators will recruit 100 HER2 positive advanced gastric cancer patientsBlood and tumor tissue will be collected at treatment baseline every time point response till disease progression All samples will be processed by next-generation sequence 10 genomics single-cell sequence whole exon sequence proteome detection and CTC detection to explore the efficacy and mechanism of anti-HER2 immunotherapy of HER2 positive GC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None